Photo: camacho9999 / iStock / Getty Images
President Donald Trump announced on Thursday (November 6) that his administration has reached an agreement with drugmakers Novo Nordisk and Eli Lilly to reduce the cost of their popular GLP-1 weight loss drugs, Wegovy and Zepbound. The deal aims to make these medications more affordable for millions of Americans struggling with obesity.
Under the agreement, the monthly out-of-pocket cost for these drugs could range from $50 to $350, depending on dosage and insurance coverage. Currently, these drugs can cost over $1,000 per month. The deal also includes plans to offer these treatments directly to consumers at a discount through a new website, TrumpRx.gov, launching in January.
The agreement is part of President Trump's "most favored nation" initiative, which seeks to align U.S. drug prices with those in other developed countries. Medicare will start covering these obesity drugs for some patients starting mid-2026, marking a significant expansion in access.
Novo Nordisk and Eli Lilly have also committed to cutting prices for all GLP-1 drugs covered by Medicare and Medicaid to $245 per month. This move is expected to benefit many patients, although experts note that the new costs may still be high for some individuals.
The Trump administration expects the direct-to-consumer pricing to be available by the end of the year, with Medicare coverage rolling out by mid-next year. This development is seen as a major step in President Trump's efforts to lower prescription drug prices and improve access to essential medications for American patients.